Inventiva SA (IVA)
| Market Cap | 614.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $15.87 |
| Previous Close | $16.07 |
| Change ($) | -0.20 |
| Change (%) | -1.24% |
| Day's Open | 16.00 |
| Day's Range | 15.44 - 17.40 |
| Day's Volume | 21,600 |
| 52-Week Range | 9.87 - 17.40 |
News
There are no news available yet.
About IVA
Inventiva S.A., a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases. Its lead product candidate is Lanifibranor that is in Phase IIb clinical trial to treat nonalcoholic steatohepatitis and systemic sclerosis. The company also develops Odiparcil, which is in Phase IIa clinical trial primarily for the treatment of mucopolysaccharidosis type VI disease; YAP-TEAD that is in preclinical stage to treat malignant mesothelioma and lung cancer; NSD2 for the treatment of multiple myeloma; and EPICURE fo... [Read more...]
| Industry Biotechnology | IPO Date Jul 10, 2020 |
| CEO Frederic Cren | Employees 86 |
| Stock Exchange NASDAQ | Ticker Symbol IVA |
Financial Performance
In 2019, Inventiva's revenue was $11.29 million, an increase of 53.02% compared to the previous year's $7.38 million. Losses were -$30.22 million, -8.47% less than in 2018.